Obstructive Sleep Apnea, Positive Airway Pressure
Conditions
Keywords
telemonitoring, big data
Brief summary
The present study aims to determine to what extent remote monitoring of PAP related to patients' clinical parameters is able to provide relevant data on predictors of compliance, subgroups of patients who may benefit from this technological tool, variations in AHI over time, occurrence of central events at the start of therapy and, in short, to shed new light on this disease and its treatment, all within the application of continuous positive pressure therapy in the real world. Among the intended objectives is the identification of phenotypes involved in the use and efficacy of PAP therapy: development of a predictive model, as well as the evaluation of the impact of long-term telemonitoring of patients with Obstructive Sleep Apnea (OSA). The study initially arose from the need to diagnose, treat and follow up patients with suspected OSA in compliance with the social distancing rules imposed by the COVID-19 pandemic. It is an ambispective cohort study, with retrospective data collection from the start date of the pandemic (March 2020) to December 2021, and prospective data collection from the approval of the protocol to December 2022.
Interventions
OTHERpatients diagnosed with OSA
All patients diagnosed with OSA since March 2020 with an indication for treatment with PAP have been telemonitored permanently since the start of therapy and continue to be telemonitored at the present time. Data are sent remotely daily to the telemonitoring platform.
Sponsors
Instituto de Investigación Marqués de Valdecilla
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Inclusion criteria
* All patients diagnosed with OSA since March 2020 with indication for treatment with PAP have been telemonitored on an ongoing basis since initiation of therapy continuing to be telemonitored at the current time.
Exclusion criteria
* Undiagnosed OSA patients
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Characterize the phenotypes involved | pandemic start date March 2020 until December 2022. | Determine the emergent CSA appearance in relation to PAP treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Establish the percentage of patients who at the first connection to the TM achieved the optimal therapeutic pressure | pandemic start date March 2020 until December 2022. | According to Built in software (BIS) of the equipment |
| Establish the Profile of patients who at the first connection to the TM achieved the optimal therapeutic pressure | pandemic start date March 2020 until December 2022. | According to Built in software (BIS) of the equipment |
| Variations in AHI during the first year of follow-up and their relationship with patient characteristics. | pandemic start date March 2020 until December 2022. | — |
| Time to achieve the optimal therapeutic pressure described after the first connection | pandemic start date March 2020 until December 2022. | Number of modifications required and their relationship with patient subgroups. |
| Evaluation of the impact of long-term telemonitoring of patients with OSA | pandemic start date March 2020 until December 2022. | Number of acesses and interventions made to the telemonitoring platform/year and time invested |
Countries
Spain
Contacts
Primary Contactmonica Gonzalez
Backup ContactLucía Lavin
Outcome results
None listed